Dr Kieran talks to ecancertv at ESMO 2016 about the results of a phase I/II trial of dabrafenib therapy, which demonstrated  higher response and lower toxicity in paediatric brain tumours.

He discusses how the BRAF inhibitor has significant impact on gliomas in children, with none of the side effects seen in adult melanoma patients, and introduces upcoming doublet trials alongside a MEK inhibitor.

Read the news story for more.